前沿论文｜CELL INTELLIGENCE

靶向 CD19 CAR-T 细胞治疗的非 ICANS 神经毒性与运动及神经认知治疗中出现的不良事件：一例病例报告

Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case

PubMed 2026/02/16 发表Front ImmunolQ1 · IF 7（JCR 2025）

靶点：CD19 靶点：CD38 靶点：BCMA 技术：CAR-T 弥漫大B细胞淋巴瘤多发性骨髓瘤淋巴瘤

肾脏病学趋势：从虚无主义到抗体介导排斥反应的靶向治疗

Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.

PubMed 2026/01/24 发表Nephrol Dial TransplantQ1 · IF 8.3（JCR 2025）

靶点：CD19 靶点：CD20 靶点：CD38 技术：NK 细胞技术：双特异性抗体多发性骨髓瘤

解析 MYC 介导的对传统抗体与 T 细胞重定向治疗性抗体的逃逸机制

Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies.

PubMed 2024/11/11 发表Int J Mol SciQ1 · IF 5.6（JCR 2025）

靶点：CD19 靶点：CD20 靶点：CD38 技术：NK 细胞技术：基因编辑技术：双特异性抗体

表征骨髓瘤患者单次运动如何影响血液中克隆性浆细胞与免疫效应细胞频率及体外达雷妥尤单抗疗效

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratu

PubMed 2024/09/19 发表Brain Behav Immun HealthQ2 · IF 3.8（JCR 2025）

靶点：CD19 靶点：CD38 技术：NK 细胞多发性骨髓瘤地区：欧洲

多发性骨髓瘤的细胞治疗：现状与未来

Cellular therapy for multiple myeloma: what's now and what's next.

PubMed 2022/12/09 发表Hematology Am Soc Hematol Educ ProgramQ1 · IF 3.7（JCR 2025）

靶点：CD19 靶点：CD38 靶点：BCMA 技术：CAR-T 技术：双特异性抗体多发性骨髓瘤

CAR 与嵌合共刺激受体联用增强 T 细胞对低抗原密度的敏感性并促进持久性

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.

PubMed 2021/12/08 发表Sci Transl MedQ1 · IF 15.6（JCR 2025）

靶点：CD19 靶点：CD38 靶点：BCMA 技术：CAR-T 急性淋巴细胞白血病多发性骨髓瘤